Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for 24 years and during that time he has conducted more than 400 early phase studies in patients and healthy volunteers; usually in the capacity of Principal Investigator since 1995. His experience ranges from first time in man (FTIM) to proof of concept (POC) studies. He has extensive experience in cardiology, neurology, gastroenterology, ethnic bridging studies.
His work currently focusses on providing expert advice in cardiac safety assessments and ethnic comparison studies. Dr Taubel is an honorary fellow at St George's University and author of over 50 publications in scientific journals. He is currently researching the role of hyperglycaemia in relation to sudden cardiac death in Type I diabetic patients. He presented his research at numerous international meetings and workshops in Europe, US and Japan.
Dr Taubel is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and the Institute of Directors (IOD). He is a Regent in the Arbeitsgemeinschaft Angewandte Humanpharmakologie (AGAH). He is a member of the (British) Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) and the Royal Society of Medicine. His international memberships include the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), the American College of Clinical Pharmacology (ACCP).
He is currently representing CCRA in the MHRA stakeholder discussions reviewing the MHRA Phase 1 Accreditation Scheme for clinical trials units in the UK. Since 1999 he has been involved in the design, programming and implementation of a pan-European research volunteer registry, designed to prevent study participants from oversubscribing to clinical studies.
He teaches on the AGAH course in Basic Pharmacology in Germany and an internal training program for junior doctors working at Richmond Pharmacology enrolled in Higher Medical Training in Pharmaceutical Medicine. He is actively participating in discussions to set up a pan-European training scheme for principal investigators jointly with the Faculty of Pharmaceutical Medicine currently involving societies in the UK, France, Belgium and Germany. He is an appraiser in the Faculty of Pharmaceutical Medicine.